Brief: Eqrx Announces New Data For Lead Oncology Programs In Non-Small Cell Lung Cancer And Rare Form Of Non-Hodgkin Lymphoma At Asco 2022

EQRx

27/05/2022 24:42

May 26 (Reuters) - EQRx Inc  EQRX.O :
    * EQRX ANNOUNCES NEW DATA FOR LEAD ONCOLOGY PROGRAMS IN
NON-SMALL
CELL LUNG CANCER AND RARE FORM OF NON-HODGKIN LYMPHOMA AT ASCO
2022
    * EQRX - IN PHASE 3 TRIAL, AUMOLERTINIB REDUCED RISK OF CNS
DISEASE PROGRESSION IN PEOPLE WITH ADVANCED EGFR-MUTATED NSCLC
BY 68% VERSUS GEFITINIB
    * EQRX -IN PHASE 3 TRIAL, ADDITION OF SUGEMALIMAB IMPROVED
MEDIAN
OS BY 8.5 MONTHS VERSUS PLACEBO PLUS CHEMOTHERAPY IN PEOPLE WITH
UNTREATED STAGE IV NSCLC
    * EQRX - IN PHASE 2 TRIAL, SUGEMALIMAB TREATMENT SHOWED
DURABLE
RESPONSES IN PEOPLE WITH RELAPSED/REFRACTORY EXTRANODAL NATURAL
KILLER/T-CELL LYMPHOMA

Source text for Eikon:  ID:nGNX1L0hfh 
Further company coverage:  EQRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))